At the news
? MIXEDIMPACT 7/10 425 filed May 19, 2026 at 10:34 ET
InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari shareholders will receive a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations. Existing INM shareholders face massive dilution but receive contingent value rights. The deal transforms the company but substantially dilutes current holders.
- Reverse merger: Mentari Therapeutics merges with INM via a two-step process, with Mentari shareholders receiving majority ownership.
- Concurrent PIPE of at least $150 million from investors, including conversion of existing convertible notes.
- INM shareholders receive contingent value rights (CVRs) for future payments.
- Mentari equity value set at $125 million (excluding PIPE proceeds), with INM parent valuation capped at $10 million.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access